PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Oxycodone with naloxone - Pain

PAD Profile : Oxycodone with naloxone - Pain

Keywords :
opioids, severe pain, idiopathic restless legs syndrome' low value medicines, drugs of low clinical value, LVM, drugs of limited clinical value, PNMP, persistent non-malignant pain
Brand Names Include :
Targinact, Myloxifin

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network does not recommend the use of oxycodone and naloxone combination product Oxycodone and Naloxone Combination Product will be considered BLACK on the traffic light system, prescribers should: o NOT initiate oxycodone and naloxone combination product for any new patient AND o De-prescribe oxycodone and naloxone combination product, with specialist support if appropriate, in all patients In exceptional circumstances where there is a clinical need for oxycodone and naloxone combination product to be prescribed in primary care this should be undertaken in a cooperation arrangement with a multidisciplinary team and / or other healthcare professional

Associated BNF Codes

04. Central Nervous System
04.07.02. Opioid analgesics
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More